checkAd

     167  0 Kommentare Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium - Seite 3

    Biophytis Contact for Investor Relations
    Evelyne Nguyen, CFO
    E: evelyne.nguyen@biophytis.com 

    Media contact
    LifeSci Advisors, LLC
    Sophie Baumont/Chris Maggos/John Hodgson
    E: sophie@lifesciadvisors.com 
    T: +33 6 27 74 74 49

    Lesen Sie auch

    Investor Relations
    LifeSci Advisors, LLC
    Sandya von der Weid
    E: svonderweid@lifesciadvisors.com 
    T: +41 78 680 05 38


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium - Seite 3 Clinical centers in France and Belgium will begin recruitment for Part 2 of the COVA Study following authorization from Regulatory AuthoritiesThese approvals follow the previous authorizations obtained from Brazil and the United States in most …